Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized Study of TLK286 versus Gefitinib in NSCLC
2004-000330-36Phase 3Active
- Sponsor
- Telik, Inc.
- Start
- Mar 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing TLK286 (TELCYTA) arm with Gefitinib arm (2 arms). Started Mar 2005; status: active.
02
Drugs
canfosfamidegefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000330-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000330-36.